BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lin D, Hu B, Li P, Zhao Y, Xu Y, Wu D. Roles of the intestinal microbiota and microbial metabolites in acute GVHD. Exp Hematol Oncol 2021;10:49. [PMID: 34706782 DOI: 10.1186/s40164-021-00240-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Weng G, Fan Z, Xue H, Huang F, Xu N, Jin H, Yu S, Ye Z, Fan J, Xuan L, Liu Q. Haploidentical donor stem cell transplantation had a lower incidence of bronchiolitis obliterans syndrome compared with HLA-matched sibling donor transplantation in patients with hematologic malignancies: Benefit from ATG? Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1036403] [Reference Citation Analysis]
2 Qiao X, Biliński J, Wang L, Yang T, Luo R, Fu Y, Yang G. Safety and efficacy of fecal microbiota transplantation in the treatment of graft-versus-host disease. Bone Marrow Transplant 2022. [PMID: 36167905 DOI: 10.1038/s41409-022-01824-1] [Reference Citation Analysis]
3 Lu Y, Ma X, Pan J, Ma R, Jiang Y. Management of dyslipidemia after allogeneic hematopoietic stem cell transplantation. Lipids Health Dis 2022;21:65. [PMID: 35918766 DOI: 10.1186/s12944-022-01665-3] [Reference Citation Analysis]
4 Dudzicz-gojowy S, Więcek A, Adamczak M. Clostridioides difficile Infection in Patients after Organ Transplantation—A Narrative Overview. JCM 2022;11:4365. [DOI: 10.3390/jcm11154365] [Reference Citation Analysis]
5 Akhremchuk KV, Skapavets KY, Akhremchuk AE, Kirsanava N, Sidarenka AV, Valentovich LN. Dynamics of gut microbiota in patients suffering from hematologic malignancies after allogeneic hematopoi-etic stem cell transplantation. Experimental Biology and Biotechnology 2022. [DOI: 10.33581/2957-5060-2022-2-48-59] [Reference Citation Analysis]
6 Li J, Zhang X, Chen Y, Zheng Q, Zhao M, Jiang H, Dominguez Perles R. A Promising Insight: The Potential Influence and Therapeutic Value of the Gut Microbiota in GI GVHD. Oxidative Medicine and Cellular Longevity 2022;2022:1-13. [DOI: 10.1155/2022/2124627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, Xu N, Zhang X, Zhang X, Xuan L, Wang S, Lin D, Deng L, Nie D, Weng J, Li Y, Zhang X, Li Y, Xiang AP, Liu Q. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol 2022;15:22. [PMID: 35255929 DOI: 10.1186/s13045-022-01240-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
8 Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21. [DOI: 10.1186/s12943-021-01489-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 47.0] [Reference Citation Analysis]